Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M84,838Revenue (TTM) $M20,837Net Margin (%)11.7Altman Z-Score3.9
Enterprise Value $M89,987EPS (TTM) $2.3Operating Margin %16.1Piotroski F-Score6
P/E(ttm)33.4Beneish M-Score-2.4Pre-tax Margin (%)14.1Higher ROA y-yN
Price/Book5.410-y EBITDA Growth Rate %11.9Quick Ratio1.2Cash flow > EarningsY
Price/Sales3.95-y EBITDA Growth Rate %-10.5Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow28.0y-y EBITDA Growth Rate %7.1ROA % (ttm)6.8Higher Current Ratio y-yY
Dividend Yield %2.7PEG--ROE % (ttm)16.3Less Shares Outstanding y-yY
Payout Ratio %88.0Shares Outstanding M1,104ROIC % (ttm)14.3Gross Margin Increase y-yN

Gurus Latest Trades with LLY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LLYKen Fisher 2016-12-31 Add0.03%$65.97 - $83.06
($74.47)
$ 76.483%Add 10.42%2,314,764
LLYJohn Paulson 2016-09-30 Buy 0.04%$76.85 - $83.4
($80.04)
$ 76.48-4%New holding45,800
LLYKen Fisher 2016-09-30 Add0.02%$76.85 - $83.4
($80.04)
$ 76.48-4%Add 5.62%2,096,406
LLYMario Gabelli 2016-09-30 Reduce$76.85 - $83.4
($80.04)
$ 76.48-4%Reduce -0.85%82,050
LLYLeucadia National 2016-06-30 Sold Out -0.04%$72.01 - $78.75
($75.23)
$ 76.482%Sold Out0
LLYKen Fisher 2016-06-30 Add0.04%$72.01 - $78.75
($75.23)
$ 76.482%Add 13.66%1,984,912
LLYDodge & Cox 2016-06-30 Reduce$72.01 - $78.75
($75.23)
$ 76.482%Reduce -5.96%29,332
LLYMario Gabelli 2016-06-30 Reduce$72.01 - $78.75
($75.23)
$ 76.482%Reduce -1.43%82,750
LLYVanguard Health Care Fund 2016-03-31 Add0.21%$69.06 - $84.26
($75.82)
$ 76.481%Add 5.49%25,959,710
LLYKen Fisher 2016-03-31 Add0.04%$69.06 - $84.26
($75.82)
$ 76.481%Add 18.63%1,746,388
LLYLeucadia National 2016-03-31 Buy 0.04%$69.06 - $84.26
($75.82)
$ 76.481%New holding3,600
LLYDavid Dreman 2016-03-31 Buy 0.01%$69.06 - $84.26
($75.82)
$ 76.481%New holding900
LLYMario Gabelli 2016-03-31 Reduce$69.06 - $84.26
($75.82)
$ 76.481%Reduce -0.47%83,950
LLYDodge & Cox 2016-03-31 Reduce$69.06 - $84.26
($75.82)
$ 76.481%Reduce -1.27%31,192
LLYVanguard Health Care Fund 2015-12-31 Add0.13%$76.98 - $87.52
($83.01)
$ 76.48-8%Add 3.16%24,609,530
LLYKen Fisher 2015-12-31 Add0.04%$76.98 - $87.52
($82.95)
$ 76.48-8%Add 18.78%1,472,117
LLYMario Gabelli 2015-12-31 Reduce-0.01%$76.98 - $87.52
($83.01)
$ 76.48-8%Reduce -13.84%84,350
LLYDavid Dreman 2015-12-31 Sold Out -0.01%$76.98 - $87.52
($83.01)
$ 76.48-8%Sold Out0
LLYDodge & Cox 2015-12-31 Reduce$76.98 - $87.52
($83.01)
$ 76.48-8%Reduce -0.13%31,592
LLYHOTCHKIS & WILEY 2015-09-30 Reduce-1.13%$78.26 - $89.98
($84.37)
$ 76.48-9%Reduce -99.30%26,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LLY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


LLY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Zakrowski Donald AChief Accounting Officer 2016-12-16Sell1,000$72.135.7view
TAI JACKSON PDirector 2016-12-16Buy1,375$72.644.96view
Mahony SusanSVP & Pres., Lilly Oncology 2016-12-16Sell20,242$72.654.94view
HOOVER R DAVIDDirector 2016-12-16Buy500$71.856.11view
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM 2016-12-16Sell2,093$82.23-7.28view
LILLY ENDOWMENT INC10% Owner 2016-12-16Sell200,000$72.595.03view
Crowe Maria APresident, Mfg. Operations 2016-10-05Sell2,248$81.37-6.3view
TAI JACKSON PDirector 2016-08-15Buy5,773$80.43-5.21view
TAI JACKSON PDirector 2016-08-12Buy2,560$80.42-5.2view
LILLY ENDOWMENT INC10% Owner 2016-07-29Sell205,000$82.94-8.08view

Press Releases about LLY :

Quarterly/Annual Reports about LLY:

News about LLY:

Articles On GuruFocus.com
Top Insider Buys of the Week Dec 24 2016 
Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Dec 10 2016 
52-Week Company Lows Nov 25 2016 
Novo Nordisk Is Being Ignored Oct 06 2016 
Sanofi Sues Merck Over Patent Infringement Sep 20 2016 
Eli Lilly's Future Is Changing Aug 30 2016 
Pharmaceuticals are the New Bonds Aug 30 2016 
Most Bought and Sold Stocks by Hedge Funds May 22 2016 
'Party Drug' Could Be Johnson & Johnson's Entry Into Antidepressant Market May 22 2016 
Sarah Ketterer Adds to Stake in Eli Lilly May 16 2016 

More From Other Websites
The Zacks Analyst Blog Highlights: Wells Fargo, Accenture, Eli Lilly, American Airlines and Domino's... Jan 17 2017
4:53 pm Eli Lilly: FDA extends review period for baricitinib, an investigational Rheumatoid... Jan 16 2017
Top Research Reports for 16th January, 2017 Jan 16 2017
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended Jan 16 2017
No new antidepressants in sight despite growing need, experts warn Jan 16 2017
Eli Lilly is the best stock in pharma: Trader Jan 13 2017
U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment Jan 13 2017
Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference Jan 13 2017
Company News for January 13, 2017 Jan 13 2017
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit Jan 13 2017
US STOCKS-Wall St falls before earnings and on U.S. policy uncertainty Jan 12 2017
US STOCKS-Wall St falls before earnings and on U.S. policy uncertainty Jan 12 2017
Eli Lilly Rebounds On Chemo-Drug Patent Win Vs. Generic Teva Jan 12 2017
Patent Victory Secures Lilly Hold on Cancer Drug Until 2022 Jan 12 2017
Investors in big pharma, biotech look to ride out Trump storm Jan 12 2017
Eli Lilly & Co. : LLY-US: Dividend Analysis : November 15th, 2016 (record date) : By the numbers :... Jan 12 2017
Eli Lilly's stock rallies after appeals court upholds favorable patent ruling Jan 12 2017
Eli Lilly Up 2% in Weak Tape on Positive Ruling Jan 12 2017
U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent Jan 12 2017
Teva loses appeal against Eli Lilly in Alimta patent case Jan 12 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)